DC-ALTOIDA/WOMEN’S-BRAIN
15.6.2022 14:02:07 CEST | Business Wire | Press release
The Women’s Brain Project , an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida , a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoida’s digital cognitive assessment platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005079/en/
Published in EPMA Journal , the study explored sex differences in Altoida’s digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimer’s Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker features, captured using Altoida’s application, achieved a 75% performance rate in predicting biological sex in healthy individuals, indicating significant differences in neurocognitive performance signatures between males and females.
The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. In this assessment domain, the accuracy reached 80 percent versus the overall neurocognitive Altoida performance. The study found that sex differences can be observed via digital biomarkers, which has the potential to impact diagnosis and treatment of AD.
“Our research shows how digital biomarkers can detect sex-based differences which are often overlooked when using standardized cognitive neuropsychological assessment,” said Antonella Santuccione Chadha, M.D., CEO and Co-Founder Women's Brain Project and Chief Medical Officer at Altoida. “These findings support the need for researchers and drug developers to account for sex-based characteristics in investigating prospective treatments for Alzheimer’s Disease.”
“Our ultimate goal is to build an integrated framework for sex-based cognitive assessment to predict, monitor and provide precision treatment of neurodegenerative disease,” said Travis Bond, CEO, Altoida. “Such a framework could be used for early detection of the disease, and enables both targeted prevention strategies and personalized Alzheimer’s treatment for patients. By integrating sex with risk stratification based on genetics and individual risk factors with the use of digital biomarker monitoring applications, this will enable the early detection and treatment of symptoms, when a patient has MCI, before development into Alzheimer’s.”
Study results highlight sex-based differences
An MCI diagnosis is determined often later in females, compared to males. This study suggests that using sex-adjusted tools for diagnosis (or sex-adjusted cut-offs) may be needed to improve diagnostic precision. Predictive diagnostics using AD biomarkers in the pre-symptomatic or oligosymptomatic (MCI) stage, followed by targeted preventions and treatment personalized to those individuals considered high risk, are increasingly considered to represent the best chance at successful AD management.
The performance dropped when this classifier was applied to more advanced stages on the AD continuum, including MCI and dementia, suggesting that sex differences might be disease-stage dependent. The results indicate that neurocognitive performance signatures built on data from digital biomarker features are different between men and women. These results stress the need to integrate traditional approaches to dementia research with digital biomarker technologies and personalized medicine perspectives to achieve more precise predictive diagnostics, targeted prevention, and customized treatment of cognitive decline.
The results may also enable researchers to better understand the pathophysiological mechanisms of the disease, which might differ between sexes, with opportunities for personalized treatment. From a predictive medicine perspective, including sex differences might make predictions more precise, especially with algorithms that incorporate multiple variables. In particular, considering sex differences may improve the ability to predict fast decliners in MCI patients, which is a key element for planning therapy and care options. From a precision medicine perspective, whether a patient is a male or female makes a difference, based on the study data. More data on sex differences could guide future clinical practice, informing choices for ad-hoc prevention, diagnosis and treatment options.
These findings should be integrated with the most powerful recent developments in digital medicine to build models of disease development that can fully integrate the effect of sex, digital biomarker technology being one of the most promising tools when developing drugs or digital therapeutics in AD. The study was conducted to show the research community that there are potential sex differences in cognitive testing in Alzheimer’s, in order to implement measures to mitigate potential biases in clinical application.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
